X-chromosome inactivation and escape

CHRISTINE M. DISTECHE[1,2,*] and **JOEL B. BERLETCH**[1]

[1]Department of Pathology, University of Washington, Seattle, WA 98195, USA

[2]Department of Medicine, University of Washington, Seattle, WA 98195, USA

Abstract

X-chromosome inactivation, which was discovered by Mary Lyon in 1961 results in random silencing of one X chromosome in female mammals. This review is dedicated to Mary Lyon, who passed away last year. She predicted many of the features of X inactivation, for e.g., the existence of an X inactivation center, the role of L1 elements in spreading of silencing and the existence of genes that escape X inactivation. Starting from her published work here we summarize advances in the field.

Keywords

X chromosome; X inactivation; escape from X inactivation

Introduction

This review is in honour of Mary Lyon who passed away last year. She has inspired my work and that of the members of my laboratory who have studied the regulation of the mammalian X chromosome. I initially met Mary Lyon in Boston when I was a post-doctoral fellow in Samuel Latt's laboratory at Harvard. Her visit was a highlight of my training. Throughout my career I continued to enjoy meeting her at the International Mammalian Genome Society conferences and the X inactivation meetings.

Lyon's law

'It is here suggested that this mosaic phenotype is due to the inactivation of one or other X chromosome early in embryonic development.'

(Lyon 1961)

'Thus, the general picture concerning heterozygotes for sex-linked genes in man is one of variable expression, which accords with the predicted result of random inactivation of one or the other X chromosome.'

(Lyon 1962)

Mary Lyon formulated her X-chromosome inactivation (XCI) hypothesis in 1961 based on her observations in female mice heterozygous for a mutation in an X-linked gene that

*For correspondence. cdistech@u.washington.edu.

controls coat colour (for e.g. tabby), and based on known facts at the time that X0 mice are viable (Welshons and Russell 1959) and that female cells contain a heteropyknotic X chromosome (Ohno and Hauschka 1960). She interpreted the variegated coat colour as due to clonal growth of cells with random silencing of one X chromosome (Lyon 1961). Similar variegation in coat colour is seen in female mice with the Cattanach X; autosome insertion (figure 1a). Mary Lyon predicted that her XCI hypothesis, now deemed a law, would be applicable to humans (Lyon 1962). A main consequence of XCI is to equalize the dosage of X-linked gene expression (dosage compensation) between male and female mammals (see Gartler, same issue). A second type of dosage compensation balances expression between X-linked genes and autosomal genes by upregulation of genes on the active X chromosome (Disteche 2012; Deng *et al.* 2014). Thus, XCI also prevents overexpression of X-linked genes in female cells with two X chromosomes (Lin *et al.* 2011). Early studies in female mouse preimplantation embryos demonstrated evidence of halving X-linked gene expression, thus pinpointing the timing of random XCI (Epstein *et al.* 1978; Kratzer and Gartler 1978). Silencing of one allele of X-linked genes is then clonally inherited in female somatic cells. Mary Lyon favoured the existence of three major steps for XCI: initiation, spreading and maintenance (Lyon 1988).

X inactivation centre and XCI initiation

'One would therefore not expect all points on the X to act independently with regards to inactivation. There might be some center or centres from which the inactivation spreads.'

(Lyon et al. 1964)

Based on analyses of X; autosome translocations in which silencing can spread into the attached autosome, both Lyon and Russell suggested the possibility of an X-inactivation centre (XIC) required for the onset of XCI (Lyon *et al.* 1964; Russell 1964). Location of the XIC on the mouse and human X chromosomes was further defined by examining patterns of XCI in multiple additional cases of X; autosome translocations or other types of X rearrangements (Brockdorff *et al.* 1991; Leppig *et al.* 1993). The search was on to find the key molecular element(s) within the XIC essential for initiation.

The main key element turned out to be a gene that encodes a long noncoding RNA (lncRNA) called X inactive-specific transcript (*Xist*). *XIST* was initially discovered in humans by Carolyn Brown and Hunt Willard who singled out this lncRNA as a critical factor for XCI based on its location within the XIC and its unique expression pattern that is completely female-specific in adult somatic cells (Brown *et al.* 1991; Brown *et al.* 1992). The homologous *Xist* gene was then identified in mice where expression was detected at a critical stage of embryo development (Brockdorff *et al.* 1992; Kay *et al.* 1993). *XIST/Xist* RNA coats the inactive X chromosome in *cis* and thus becomes detectable as a cloud within the nucleus of somatic cells using RNA-FISH (Clemson *et al.* 1996) (figure 1b). Subsequent studies showed that insertion of the XIC including *Xist* on autosomes induces silencing at great distances, and that deletions/mutations of *Xist* perturbs XCI (Penny *et al.* 1996; Lee and Jaenisch 1997). The role of *Xist* and of all elements of the XIC which include several other lncRNAs and controlling elements is still under study (Payer and Lee 2008; Gendrel

and Heard 2014). In mice, where there are two waves of silencing in early development imprinted XCI is initiated on the paternal X chromosome at day four after fertilization (Okamoto *et al.* 2005). Imprinted paternal XCI persists in extraembryonic tissues (Takagi and Sasaki 1975; West *et al.* 1977), while it is followed by X reactivation in the inner cell mass and random XCI at the blastocyst stage (Mak *et al.* 2004). XCI depends on levels of *Xist* expression, which are controlled by its antisense *Tsix* and a series of lncRNAs located at the XIC (Galupa and Heard 2015). The XIC also contains the protein-coding gene *Rnf12*, whose product activates *Xist* expression based on its dosage (Gontan *et al.* 2012). Pluripotency factors such as OCT4 and NANOG control *Xist* and *Tsix* expression, preventing XCI in pluripotent cells such as embryonic stem (ES) cells (Navarro *et al.* 2008). Induced differentiation of cultured ES cells triggers the onset of random XCI, which has greatly facilitated experimentation.

Surprisingly, in human and rabbit, XCI onset is delayed and the paternal or maternal X chromosome is randomly silenced in some cells at early stages of development (Okamoto *et al.* 2011), thus skipping the imprinted XCI observed in mouse. The organization and function of the XIC also differ between human and mouse. Whereas the antisense *Tsix* RNA and/or its transcription are critical for regulation of *Xist* in mouse, this is not the case in human (Chang and Brown 2010). Important questions remain, for e.g., about mechanisms that ensures that only one active X per diploid set of autosomes persists. *Tsix* may protect the active X from silencing (Gayen *et al.* 2015). The choice of which X chromosome becomes silenced is also under study; one important element is the X controlling element (*Xce*) locus (Cattanach 1975) whose molecular identity remains elusive (Morey and Avner 2010; Thorvaldsen *et al.* 2012). One possibility is that structural oscillations in topological domains at the XIC may influence choice in individual cells (Giorgetti *et al.* 2014). It has also been proposed that initiation of XCI may be stochastic, with subsequent selection of cells with the appropriate number of X chromosomes expressed, i.e. a single X chromosome per diploid cell (Monkhorst *et al.* 2008).

XCI spreading

> 'It is suggested that interspersed repetitive elements of the LINE type, in which the X chromosome is particularly rich, act as booster elements to promote the spread of XIST mRNA.'
>
> (Lyon 1998)

Gartler and Riggs originally proposed that there would be way-stations that help spreading of silencing along the inactive X chromosome (Gartler and Riggs 1983). However, how exactly *Xist* RNA spreads along the X chromosome is still controversial (Engreitz *et al.* 2013; Simon *et al.* 2013). One possibility is that *Xist* RNA binds to preferred sites in a saltatory way and spreads from a limited number of recruitment sites (Pinter *et al.* 2012). High resolution microscopy of single cells show fewer *Xist* RNA molecules over the inactive X chromosome than expected from previous studies on bulk cells, suggesting a hit-and-run model (Sunwoo *et al.* 2015). Importantly, new studies have identified proteins recruited by *Xist* RNA, which directly or indirectly facilitate gene silencing (Chu *et al.* 2015; McHugh *et al.* 2015; Minajigi *et al.* 2015). For example, SHARP (also called SPEN) interacts with *Xist*

RNA and recruit SMRT that activates the histone deacetylase HDAC3 for silencing (McHugh *et al.* 2015). Among the most enriched proteins recruited by *Xist* RNA is the nuclear matrix protein HnrnpK, which is involved in recruitment of the PRC1 and PRC2 complexes for deposition of the repressive marks H2AK119ub and H3K27me3 (Hasegawa *et al.* 2010; Chu *et al.* 2015; McHugh *et al.* 2015; Minajigi *et al.* 2015). Histone modifications including deacetylation of histones, methylation of H3K27 and ubiquitination of H3K119 are early events in establishing silencing (Jeppesen and Turner 1993; Boggs *et al.* 2002; Plath *et al.* 2002; Heard and Disteche 2006; Marks *et al.* 2009). The A-repeat within the *Xist* gene is essential for gene silencing (Wutz *et al.* 2002) and is a key element for the binding interactors (Chu *et al.* 2015). Thus, important new elements are being discovered that connect *Xist* RNA to the deposition of specific epigenetic modifications put in place to implement stable and heritable gene silencing (see maintenance) (Gendrel and Heard 2014).

> '... and that there will be a similar effect when autosomal genes are translocated to the X-chromosome'
>
> (Lyon 1961)

Silencing via *XIST/Xist* RNA spreading in *cis* can also recruit silencing factors along autosomal segments attached to the inactive X following a translocation or insertion (figure 1a). Silencing is less efficient along autosomal regions (Sharp *et al.* 2002), suggesting that specific elements enriched on the X help spreading and maintenance. Mary Lyon proposed that such elements might be LINE1 repeats, which are particularly abundant on the X chromosome (Lyon 1998). Indeed, the core of the condensed inactive X chromosome is enriched in L1 elements (Chow *et al.* 2010; Deng *et al.* 2015). Accordingly, inefficient discontinuous spreading is observed along autosomal segments with few L1 elements (Tang *et al.* 2010). However, cell selection plays an important role in the observed patterns of inactivation in X;autosome translocations, which should be interpreted with caution (Disteche *et al.* 1979). An interesting application of the power of *XIST* in inducing *cis* autosomal silencing is the correction of trisomy 21 by insertion of a highly expressed *XIST* transgene on one human chromosome 21 in trisomic cells (Jiang *et al.* 2013). This restores normal gene expression and cellular phenotypes, thus offering hope for helping individuals with Down's syndrome or other autosomal trisomies, at least in cells accessible to treatment such as bone marrow.

XCI maintenance

> 'Thus, it is at present considered that methylation is part of the mechanism for stabilizing inactivation, after spreading has occurred'
>
> (Lyon 1992)

Early studies identified a key molecular feature that locks silencing, i.e. DNA methylation at CpG islands of X-linked genes (Riggs 1975; Gartler and Riggs 1983). Particularly telling were experiments in which a methylated DNA plasmid containing the X-linked gene *HPRT* was shown to remain silent after transfection into HPRT-deficient cells, but became competent after removal of DNA methylation by 5-azacytidine (Liskay and Evans 1980; Venolia *et al.* 1982; Venolia and Gartler 1983). Maintenance of XCI is also ensured by the

histone modifications that are progressively added throughout early development (see spreading). Later events include replacement of histone H2A by macrohistone H2A (Costanzi and Pehrson 1998), and DNA methylation of CpG islands implemented by the methylases Dnmt3a/b and maintained by Dnmt1 (Norris *et al.* 1991). Different genes become silent at different times in concordance with epigenetic changes (Gendrel *et al.* 2012). Maintenance of XCI requires synergy of *Xist* RNA, histone modifications and DNA methylation (Csankovszki *et al.* 2001). However, loss of any one of the element does not necessarily affect silencing. For example, EED, a component of the PRC2 complex that mediate H3K27me3 is dispensable for initiation and maintenance of XCI in embryos (Kalantry *et al.* 2006).

X chromosome 3D structure

> *'The cytology evidence was provided by* Ohno and Hauschka (1960), *who showed that in cells of various tissues of female mice one chromosome was heteropycnotic.'*
>
> (Lyon 1962)

The inactive X chromosome forms the Barr body (Barr and Bertram 1949) visible as a condensed heteropycnotic structure in interphase nuclei of female cells (Ohno and Hauschka 1960). The modalities of condensation of the inactive X are only beginning to be deciphered using genome-wide analyses of chromatin structure by chromatin conformation studies including Hi-C. Both in human and mouse, the inactive X chromosome forms a bipartite structure of two super-domains separated by a boundary (Rao *et al.* 2014; Deng *et al.* 2015; Minajigi *et al.* 2015). The superdomains differ between human and mouse but the boundary between domains is partially conserved and contains the macrosatellite locus *Dxz4* (Deng *et al.* 2015), which binds CTCF specifically on the inactive X (Chadwick 2008; Horakova *et al.* 2012a, b). CTCF is a zinc finger protein widely known to help organize chromatin in topologically associated domains (TADs) (Dixon *et al.* 2012). In mouse, the boundary between superdomains on the inactive X appears to represent a nucleolus-associated domain (NAD) (Deng *et al.* 2015).

> 'Knowledge of the fine structure of the embryo at this stage may provide some clue whether or not attachment of the X chromosome to a site is a likey mechanism'
>
> (Lyon 1971)

Mary Lyon suggested that the inactive X may occupy a preferred site in the nucleus (Lyon 1971). Such preferred locations for the inactive X are proximity to either the nuclear membrane (Barr and Bertram 1949) or the nucleolus (Zhang *et al.* 2007). These preferred locations are in agreement with findings in other systems, suggesting that the lamina and/or the nucleolus represent 'Velcro' elements for heterochromatin (Padeken and Heun 2014). Interestingly, *XIST* interactors include proteins that help anchor chromosomes to the nuclear membrane such as the lamin B receptor (LBR) (Chu *et al.* 2015; McHugh *et al.* 2015; Minajigi *et al.* 2015). Our own data suggest that proximity of the inactive X to the nucleolus may be facilitated by specific elements such as the lncRNA genes, *Firre* and *Dxz4*, which bind CTCF specifically on the inactive X. Knockdown of *Firre* causes loss of the repressive

mark H3K27me3 on the X chromosome, suggesting a role in maintenance of heterochromatin potentially related to positioning (Yang *et al.* 2015).

X reactivation

'These observations provide the first evidence with a true X-linked gene (Oct) for an age-related decrease in the stability of the X-inactivation mechanism.'

(Wareham et al. 1987)

X chromosome regulation in females represents a cycle of inactivation and reactivation (Gartler and Riggs 1983; Gartler *et al.* 1992). In precursor female germ cells both X chromosomes become active by a process of reactivation that progresses along the X, genes closest to *Xist* being reactivated last (Sugimoto and Abe 2007). This reactivation ensures that each haploid female germ cell contains an active X chromosome. Interestingly, haploid cells derived from female germ cells have a high X:autosome expression ratio due to upregulation of the active X (Leeb and Wutz 2011). Immediately after fertilization, there is reactivation of the paternal X which is largely silenced in sperm (Okamoto *et al.* 2004). A second wave of reactivation occurs in the inner cell mass at blastocyst stage prior to the onset of random XCI (Mak *et al.* 2004). In cells where reactivation occurs *XIST* becomes silent and repressive histone marks are lost (Ohhata and Wutz 2012).

X reactivation can also occur in somatic cells in relation to ageing as Mary Lyon first described (Wareham *et al.* 1987). Aberrant reactivation is also observed in congenital or acquired diseases (see below). For example, abnormal X-linked gene expression is seen in ICF syndrome, which is due to a mutation in the methylase Dnmt3b (Hansen *et al.* 2000). Persistence of *XIST/Xist* in somatic cells is not necessarily required for stable silencing (Brown and Willard 1994). However, an induced *Xist* deletion caused X reactivation and cancer in mice after a long period of time (Yildirim *et al.* 2013). Reactivation can also be induced in iPS cells following dedifferentiation of somatic cells (Lessing and Lee 2013). While this can easily be induced in mouse by adding pluripotent factors this is not always the case in human cells where variable patterns are observed (Lessing and Lee 2013). The presence of two active X chromosomes is rarely observed in undifferentiated human ES cell lines unless they are in a 'naive' state (Ware *et al.* 2014). Interestingly, X reactivation in human pluripotent stem cells is accompanied by coating with the lncRNA *XACT* prior to loss of *XIST* RNA (Vallot *et al.* 2015).

Escape from XCI

'… it is still possible that inactivation of one X does not take place in man, or that it differs in some way from the process in the mouse... '

'The other possible explanation is that the X chromosome of man has a short pairing segment, that is not normally inactivated, and that it is duplication or deficiency of this region which gives rise to the abnormal phenotypes observed.'

(Lyon 1962)

Mary Lyon hypothesized that some genes, probably located in the pseudoautosomal region (PAR) of pairing between the X and Y chromosomes, would escape XCI (Lyon 1962). She puzzled about differences in phenotypes between X0 mice that can reproduce and 45,X women who have abnormal phenotypes and are infertile. Subsequent studies have shown that the mouse and human PARs contain very different sets of genes (Disteche *et al.* 1992). In addition, genes outside the PAR can also escape XCI with significant differences in the list of escape genes between mouse and human (Berletch *et al.* 2010). In human, about 15% of X-linked genes escape XCI compared to 3–7% in mouse (Carrel *et al.* 1999; Yang *et al.* 2010). Some of the escape genes that reside outside of the PAR have retained a Y-linked paralogue (Lahn and Page 1997). In fact, a subset of these X/Y genes are conserved on the sex chromosomes in multiple mammalian species, possibly because they encode for critical proteins and are highly dosage-sensitive (Bellott *et al.* 2014; Cortez *et al.* 2014).

Escape from XCI can vary between tissues and individuals. We recently completed a study of XCI and escape in multiple mouse tissues using RNA-seq to test allele-specific expression in F_1 mice with skewed XCI based on frequent SNPs (figure 2) (Berletch *et al.* 2015). While, a subset of escape genes were common between tissues, others were tissue-specific. Interestingly, many genes found to escape XCI in adult mouse tissues differ from those reported in trophoblastic cells derived from placenta in which XCI is paternally imprinted, suggesting significant differences between imprinted and random XCI (Calabrese *et al.* 2012; Corbel *et al.* 2013; Finn *et al.* 2014). In addition, levels of expression from the inactive X can vary for a given gene, suggesting tissue-specific dosage effects of escape. Thus, escape from XCI may be a source of tissue-specific sex differences. In human, SNP analyses have also shown tissue and individual variability (Cotton *et al.* 2013). Differential methylation levels at X-linked CpG islands and gene bodies has also helped identify escape genes in many human tissue types (Lister *et al.* 2013; Cotton *et al.* 2015; Schultz *et al.* 2015). Indeed, escape genes are often depleted in repressive marks associated with XCI and enriched in marks associated with active gene transcription (Berletch *et al.* 2011). In addition, escape genes are located at the periphery of the silent domain of the inactive X chromosome where they apparently interact with each other (Splinter *et al.* 2011; Deng *et al.* 2015).

Escape genes that lack a functionally equivalent Y paralogue are a potential source of sex-specific differences in gene expression and thus, candidates for sex-specific phenotypes (Berletch *et al.* 2011). One example is the histone demethylase KDM6A encoded by a gene that escapes XCI in multiple species. *Kdm6a* is more highly expressed in female cells and regulates a set of reproduction-related homeobox genes (*Rhox6* and *Rhox9*) in a female-specific manner (Berletch *et al.* 2013). Whether other escape genes contribute to sex-specific differences is still under study.

XCI, X aneuploidy and disease

'Facts that remain unexplained are that an X0 female and an XXY male show any abnormality, and that an X0 female in man differs in phenotype from that in mouse'

(Lyon 1962)

Escape gene dosage is dependent on the number of X chromosomes present, thus escape genes are candidates for phenotypes associated with X aneuploidy. Indeed, aberrant copy number of escape genes (PAR or non-PAR) is thought to be associated with abnormal phenotypes in Turner and Klinefelter syndromes (Zinn *et al.* 2007; Tartaglia *et al.* 2010a, b). For example, loss of one copy of the *SHOX* gene located in the PAR explains the short stature in Tuner syndrome, whereas three copies of this gene in XXY individuals explain the tall stature in Klinefelter syndrome (Blaschke and Rappold 2006). Specific escape genes have been implicated in mental impairment; for example, *KDM5C* and *IQSEC2* deletions or mutations cause X-linked intellectual disability both in males and females, consistent with dosage sensitivity (Santos-Reboucas *et al.* 2011; Simensen *et al.* 2013; Fieremans *et al.* 2015). Further, cognitive deficiencies have been reported in individuals carrying microduplications of *KDM5C* and *IQSEC2* associated with abnormally high expression (Moey *et al.* 2015). Similarly, mutations and deletions in *KDM6A* have been discovered in patients with Kabuki syndrome characterized by intellectual disability, growth retardation, skeletal abnormalities, and visceral malformations (Lederer *et al.* 2012; Miyake *et al.* 2012). Female carrier of mutations also show abnormalities, consistent with dosage anomalies (Lindgren *et al.* 2013). Some of these patients show symptoms overlapping with Turner syndrome, termed Turner–Kabuki syndrome, suggesting a potential link to other genes that escape XCI.

X-linked mutations cause diseases with widely different consequences in males and females. Males are often affected because they have only one X chromosome, so that recessive mutations cause abnormal phenotypes. Females can compensate by having patches of cells that express the normal allele, or by strong selection (skewing) for cells that express the normal allele (Deng *et al.* 2014). Skewing of XCI can be very extensive or only affect the tissue in which proper expression is critical (Migeon 2014). Random distribution of patches of cells with one X active can be extensive as shown by a recent study of female mice with a different X-linked fluorescent reporter on each allele, in which *in situ* visualization of XCI distribution revealed surprisingly extensive skewing of XCI (Wu *et al.* 2014). For example, one mouse had half of her brain with silencing of the maternal X and the other with silencing of the paternal X.

Mutations in escape genes and abnormal dosage have been linked to noncongenital disease as well. For example, *KDM6A* mutations have been observed in renal carcinoma as well as other cancer types (van Haaften *et al.* 2009; Dalgliesh *et al.* 2010). Interestingly, KDM6A seems to function as a gender-specific tumour suppressor in T-cell acute lymphoblastic leukaemia, where only males with the disease had inactivating mutations in the demethylase (Van der Meulen *et al.* 2015). Additionally, aberrant hypomethylation of the X chromosome along with loss of part or one entire X can occur in breast cancer cells (Sun *et al.* 2015). Extensive reactivation of the X chromosome has been documented in breast cancer (Chaligne *et al.* 2015).

Summary

In summary, the X chromosome inactivation law proposed by Mary Lyon has helped us to understand not only basic principles of gene silencing, heterochromatin structure and

nuclear organization, but has also led to discoveries of new master switches such as the lncRNA *Xist* and to a better understanding of X-linked diseases and of sex-specific differences.

Acknowledgments

References

Barr ML, Bertram EG. A morphological distinction between neurones of the male and female, and the behaviour of the nucleolar satellite during accelerated nucleoprotein synthesis. Nature. 1949; 163:676. [PubMed: 18120749]

Bellott DW, Hughes JF, Skaletsky H, Brown LG, Pyntikova T, Cho TJ, et al. Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators. Nature. 2014; 508:494–499. [PubMed: 24759411]

Berletch JB, Yang F, Disteche CM. Escape from X inactivation in mice and humans. Genome Biol. 2010; 11:213. [PubMed: 20573260]

Berletch JB, Yang F, Xu J, Carrel L, Disteche CM. Genes that escape from X inactivation. Hum Genet. 2011; 130:237–245. [PubMed: 21614513]

Berletch JB, Deng X, Nguyen DK, Disteche CM. Female bias in Rhox6 and 9 regulation by the histone demethylase KDM6A. PLoS Genet. 2013; 9:e1003489. [PubMed: 23658530]

Berletch JB, Ma W, Yang F, Shendure J, Noble WS, Disteche CM, Deng X. Escape from X inactivation varies in mouse tissues. PLoS Genet. 2015; 11:e1005079. [PubMed: 25785854]

Blaschke RJ, Rappold G. The pseudoautosomal regions, SHOX and disease. Curr Opin Genet Dev. 2006; 16:233–239. [PubMed: 16650979]

Boggs BA, Cheung P, Heard E, Spector DL, Chinault AC, Allis CD. Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes. Nat Genet. 2002; 30:73–76. [PubMed: 11740495]

Brockdorff N, Kay G, Smith S, Keer JT, Hamvas RM, Brown SD, Rastan S. High-density molecular map of the central span of the mouse X chromosome. Genomics. 1991; 10:17–22. [PubMed: 1675191]

Brockdorff N, Ashworth A, Kay GF, McCabe VM, Norris DP, Cooper PJ, et al. The product of the mouse *Xist* gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus. Cell. 1992; 71:515–526. [PubMed: 1423610]

Brown CJ, Willard HF. The human X-inactivation center is not required for maintenance of X-chromosome inactivation. Nature. 1994; 368:154–156. [PubMed: 8139659]

Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R, Willard HF. A gene from the region of the human X inactivation center is expressed exclusively from the inactive X chromosome. Nature. 1991; 349:38–44. [PubMed: 1985261]

Brown CJ, Hendrich BD, Rupert JL, Lafreniere RG, Xing Y, Lawrence J, Willard HF. The human *XIST* gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. Cell. 1992; 71:527–542. [PubMed: 1423611]

Calabrese JM, Sun W, Song L, Mugford JW, Williams L, Yee D, et al. Site-specific silencing of regulatory elements as a mechanism of X inactivation. Cell. 2012; 151:951–963. [PubMed: 23178118]

Carrel L, Cottle AA, Goglin KC, Willard HF. A first-generation X-inactivation profile of the human X chromosome. Proc Natl Acad Sci USA. 1999; 96:14440–14444. [PubMed: 10588724]

Cattanach BM. Control of chromosome inactivation. Annu Rev Genet. 1975; 9:1–18. [PubMed: 1108761]

Chadwick BP. DXZ4 chromatin adopts an opposing conformation to that of the surrounding chromosome and acquires a novel inactive X-specific role involving CTCF and antisense transcripts. Genome Res. 2008; 18:1259–1269. [PubMed: 18456864]

Chaligne R, Popova T, Mendoza-Parra MA, Saleem MA, Gentien D, Ban K, et al. The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer. Genome Res. 2015; 25:488–503. [PubMed: 25653311]

Chang SC, Brown CJ. Identification of regulatory elements flanking human *XIST* reveals species differences. BMC Mol Biol. 2010; 11:20. [PubMed: 20211024]

Chow JC, Ciaudo C, Fazzari MJ, Mise N, Servant N, Glass JL, et al. LINE-1 activity in facultative heterochromatin formation during X chromosome inactivation. Cell. 2010; 141:956–969. [PubMed: 20550932]

Chu C, Zhang QC, da Rocha ST, Flynn RA, Bharadwaj M, Calabrese JM, et al. Systematic discovery of *Xist* RNA binding proteins. Cell. 2015; 161:404–416. [PubMed: 25843628]

Clemson CM, McNeil JA, Willard HF, Lawrence JB. *XIST* RNA paints the inactive X chromosome at interphase: evidence for a novel RNA involved in nuclear/chromosome structure. J Cell Biol. 1996; 132:259–275. [PubMed: 8636206]

Corbel C, Diabangouaya P, Gendrel AV, Chow JC, Heard E. Unusual chromatin status and organization of the inactive X chromosome in murine trophoblast giant cells. Development. 2013; 140:861–872. [PubMed: 23362347]

Cortez D, Marin R, Toledo-Flores D, Froidevaux L, Liechti A, Waters PD, et al. Origins and functional evolution of Y chromosomes across mammals. Nature. 2014; 508:488–493. [PubMed: 24759410]

Costanzi C, Pehrson JR. Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals. Nature. 1998; 393:599–601. [PubMed: 9634239]

Cotton AM, Ge B, Light N, Adoue V, Pastinen T, Brown CJ. Analysis of expressed SNPs identifies variable extents of expression from the human inactive X chromosome. Genome Biol. 2013; 14:R122. [PubMed: 24176135]

Cotton AM, Price EM, Jones MJ, Balaton BP, Kobor MS, Brown CJ. Landscape of DNA methylation on the X chromosome reflects CpG density, functional chromatin state and X-chromosome inactivation. Hum Mol Genet. 2015; 24:1528–1539. [PubMed: 25381334]

Csankovszki G, Nagy A, Jaenisch R. Synergism of *Xist* RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. J Cell Biol. 2001; 153:773–784. [PubMed: 11352938]

Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010; 463:360–363. [PubMed: 20054297]

Deng X, Berletch JB, Nguyen DK, Disteche CM. X chromosome regulation: diverse patterns in development, tissues and disease. Nat Rev Genet. 2014; 15:367–378. [PubMed: 24733023]

Deng X, Ma W, Ramani V, Hill A, Yang F, Ay F, et al. Bipartite structure of the inactive mouse X chromosome. Genome Biol. 2015; 16:152. [PubMed: 26248554]

Disteche CM. Dosage compensation of the sex chromosomes. Annu Rev Genet. 2012; 46:537–560. [PubMed: 22974302]

Disteche CM, Brannan CI, Larsen A, Adler DA, Schorderet DF, Gearing D, et al. The human pseudoautosomal GM-CSF receptor alpha subunit gene is autosomal in mouse. Nat Genet. 1992; 1:333–336. [PubMed: 1363815]

Disteche CM, Eicher EM, Latt SA. Late replication in an X-autosome translocation in the mouse: correlation with genetic inactivation and evidence for selective effects during embryogenesis. Proc Natl Acad Sci USA. 1979; 76:5234–5238. [PubMed: 291940]

Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature. 2012; 485:376–380. [PubMed: 22495300]

Engreitz JM, Pandya-Jones A, McDonel P, Shishkin A, Sirokman K, Surka C, et al. The *Xist* lncRNA exploits three-dimensional genome architecture to spread across the X chromosome. Science. 2013; 341:1237973. [PubMed: 23828888]

Epstein CJ, Smith S, Travis B, Tucker G. Both X chromosomes function before visible X-chromosome inactivation in female mouse embryos. Nature. 1978; 274:500–503. [PubMed: 672979]

Fieremans N, Van Esch H, de Ravel T, Van Driessche J, Belet S, Bauters M, Froyen G. Microdeletion of the escape genes KDM5C and IQSEC2 in a girl with severe intellectual disability and autistic features. Eur J Med Genet. 2015; 58:324–327. [PubMed: 25858702]

Finn EH, Smith CL, Rodriguez J, Sidow A, Baker JC. Maternal bias and escape from X chromosome imprinting in the midgestation mouse placenta. Dev Biol. 2014; 390:80–92. [PubMed: 24594094]

Galupa R, Heard E. X-chromosome inactivation: new insights into cis and trans regulation. Curr Opin Genet Dev. 2015; 31:57–66. [PubMed: 26004255]

Gartler SM, Dyer KA, Goldman MA. Mammalian X chromosome inactivation. Mol Genet Med. 1992; 2:121–160. [PubMed: 1458223]

Gartler SM, Riggs AD. Mammalian X-chromosome inactivation. Annu Rev Genet. 1983; 17:155–190. [PubMed: 6364959]

Gayen S, Maclary E, Buttigieg E, Hinten M, Kalantry S. A primary role for the Tsix lncRNA in maintaining random X-chromosome inactivation. Cell Rep. 2015; 11:1251–1265. [PubMed: 25981039]

Gendrel AV, Heard E. Noncoding RNAs and epigenetic mechanisms during X-chromosome inactivation. Annu Rev Cell Dev Biol. 2014; 30:561–580. [PubMed: 25000994]

Gendrel AV, Apedaile A, Coker H, Termanis A, Zvetkova I, Godwin J, et al. Smchd1-dependent and -independent pathways determine developmental dynamics of CpG island methylation on the inactive x chromosome. Dev Cell. 2012; 23:265–279. [PubMed: 22841499]

Giorgetti L, Galupa R, Nora EP, Piolot T, Lam F, Dekker J, et al. Predictive polymer modeling reveals coupled fluctuations in chromosome conformation and transcription. Cell. 2014; 157:950–963. [PubMed: 24813616]

Gontan C, Achame EM, Demmers J, Barakat TS, Rentmeester E, van IW, et al. RNF12 initiates X-chromosome inactivation by targeting REX1 for degradation. Nature. 2012; 485:386–390. [PubMed: 22596162]

Hansen RS, Stoger R, Wijmenga C, Stanek AM, Canfield TK, Luo P, et al. Escape from gene silencing in ICF syndrome: evidence for advanced replication time as a major determinant. Hum Mol Genet. 2000; 9:2575–2587. [PubMed: 11063717]

Hasegawa Y, Brockdorff N, Kawano S, Tsutui K, Tsutui K, Nakagawa S. The matrix protein hnRNP U is required for chromosomal localization of *Xist* RNA. Dev Cell. 2010; 19:469–476. [PubMed: 20833368]

Heard E, Disteche CM. Dosage compensation in mammals: fine-tuning the expression of the X chromosome. Genes Dev. 2006; 20:1848–1867. [PubMed: 16847345]

Horakova AH, Calabrese JM, McLaughlin CR, Tremblay DC, Magnuson T, Chadwick BP. The mouse DXZ4 homolog retains Ctcf binding and proximity to Pls3 despite substantial organizational differences compared to the primate macrosatellite. Genome Biol. 2012a; 13:R70. [PubMed: 22906166]

Horakova AH, Moseley SC, McLaughlin CR, Tremblay DC, Chadwick BP. The macrosatellite DXZ4 mediates CTCF-dependent long-range intrachromosomal interactions on the human inactive X chromosome. Hum Mol Genet. 2012b; 21:4367–4377. [PubMed: 22791747]

Jeppesen P, Turner BM. The inactive X chromosome in female mammals is distinguished by a lack of histone H4 acetylation, a cytogenetic marker for gene expression. Cell. 1993; 74:281–289. [PubMed: 8343956]

Jiang J, Jing Y, Cost GJ, Chiang JC, Kolpa HJ, Cotton AM, et al. Translating dosage compensation to trisomy 21. Nature. 2013; 500:296–300. [PubMed: 23863942]

Kalantry S, Mills KC, Yee D, Otte AP, Panning B, Magnuson T. The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation. Nat Cell Biol. 2006; 8:195–202. [PubMed: 16415857]

Kay GF, Penny GD, Patel D, Ashworth A, Brockdorff N, Rastan S. Expression of *Xist* during mouse development suggests a role in the initiation of X chromosome inactivation. Cell. 1993; 72:171–182. [PubMed: 8425217]

Kratzer PG, Gartler SM. HGPRT activity changes in preimplantation mouse embryos. Nature. 1978; 274:503–504. [PubMed: 580953]

Lahn BT, Page DC. Functional coherence of the human Y chromosome. Science. 1997; 278:675–680. [PubMed: 9381176]

Lederer D, Grisart B, Digilio MC, Benoit V, Crespin M, Ghariani SC, et al. Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome. Am J Hum Genet. 2012; 90:119–124. [PubMed: 22197486]

Lee JT, Jaenisch R. Long-range cis effects of ectopic X-inactivation centers on a mouse autosome. Nature. 1997; 386:275–279. [PubMed: 9069285]

Leeb M, Wutz A. Derivation of haploid embryonic stem cells from mouse embryos. Nature. 2011; 479:131–134. [PubMed: 21900896]

Leppig KA, Brown CJ, Bressler SL, Gustashaw K, Pagon RA, Willard HF, Disteche CM. Mapping of the distal boundary of the X-inactivation center in a rearranged X chromosome from a female expressing *XIST*. Hum Mol Genet. 1993; 2:883–887. [PubMed: 8364571]

Lessing D, Lee JT. X chromosome inactivation and epigenetic responses to cellular reprogramming. Annu Rev Genomics Hum Genet. 2013; 14:85–110. [PubMed: 23662665]

Lin H, Halsall JA, Antczak P, O'Neill LP, Falciani F, Turner BM. Relative overexpression of X-linked genes in mouse embryonic stem cells is consistent with Ohno's hypothesis. Nat Genet. 2011; 43:1169–1170. author reply 1171–1172. [PubMed: 22120049]

Lindgren AM, Hoyos T, Talkowski ME, Hanscom C, Blumenthal I, Chiang C, et al. Haploinsufficiency of KDM6A is associated with severe psychomotor retardation, global growth restriction, seizures and cleft palate. Hum Genet. 2013; 132:537–552. [PubMed: 23354975]

Liskay RM, Evans RJ. Inactive X chromosome DNA does not function in DNA-mediated cell transformation for the hypoxanthine phosphoribosyltransferase gene. Proc Natl Acad Sci USA. 1980; 77:4895–4898. [PubMed: 6933537]

Lister R, Mukamel EA, Nery JR, Urich M, Puddifoot CA, Johnson ND, et al. Global epigenomic reconfiguration during mammalian brain development. Science. 2013; 341:1237905. [PubMed: 23828890]

Lyon M. Gene action in the X-chromosome of the mouse (*Mus musculus* L). Nature. 1961; 190:372–373. [PubMed: 13764598]

Lyon MF. Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet. 1962; 14:135–148. [PubMed: 14467629]

Lyon MF. Possible mechanisms of X chromosome inactivation. Nat New Biol. 1971; 232:229–232. [PubMed: 5286191]

Lyon MF. The William Allan memorial award address: X-chromosome inactivation and the location and expression of X-linked genes. Am J Hum Genet. 1988; 42:8–16. [PubMed: 3276178]

Lyon MF. Some milestones in the history of X-chromosome inactivation. Annu Rev Genet. 1992; 26:16–28. [PubMed: 1482111]

Lyon MF. X-chromosome inactivation: a repeat hypothesis. Cytogenet Cell Genet. 1998; 80:133–137. [PubMed: 9678347]

Lyon MF, Searle AG, Ford CE, Ohno S. A mouse translocation suppressing sex-linked variegation. Cytogenetics. 1964; 3:306–323. [PubMed: 14248461]

Mak W, Nesterova TB, de Napoles M, Appanah R, Yamanaka S, Otte AP, Brockdorff N. Reactivation of the paternal X chromosome in early mouse embryos. Science. 2004; 303:666–669. [PubMed: 14752160]

Marks H, Chow JC, Denissov S, Francoijs KJ, Brockdorff N, Heard E, Stunnenberg HG. High-resolution analysis of epigenetic changes associated with X inactivation. Genome Res. 2009; 19:1361–1373. [PubMed: 19581487]

McHugh CA, Chen CK, Chow A, Surka CF, Tran C, McDonel P, et al. The *Xist* lncRNA interacts directly with SHARP to silence transcription through HDAC3. Nature. 2015; 521:232–236. [PubMed: 25915022]

Migeon, BR. Females are mosaic: X inactivation and sex differences in disease. Oxford University Press; Oxford: 2014.

Minajigi A, Froberg JE, Wei C, Sunwoo H, Kesner B, Colognori D, et al. A comprehensive *Xist* interactome reveals cohesin repulsion and an RNA-directed chromosome conformation. Science. 2015 pii, aab2276.

Miyake N, Mizuno S, Okamoto N, Ohashi H, Shiina M, Ogata K, et al. KDM6A point mutations cause Kabuki syndrome. Hum Mutat. 2012; 34:108–110. [PubMed: 23076834]

Moey C, Hinze SJ, Brueton L, Morton J, McMullan DJ, Kamien B, et al. Xp11.2 microduplications including IQSEC2, TSPYL2 and KDM5C genes in patients with neurodevelopmental disorders. Eur J Hum Genet. 2015 in press.

Monkhorst K, Jonkers I, Rentmeester E, Grosveld F, Gribnau J. X inactivation counting and choice is a stochastic process: evidence for involvement of an X-linked activator. Cell. 2008; 132:410–421. [PubMed: 18267073]

Morey C, Avner P. Genetics and epigenetics of the X chromosome. Ann N Y Acad Sci. 2010; 1214:E18–E33. [PubMed: 21382199]

Navarro P, Chambers I, Karwacki-Neisius V, Chureau C, Morey C, Rougeulle C, Avner P. Molecular coupling of *Xist* regulation and pluripotency. Science. 2008; 321:1693–1695. [PubMed: 18802003]

Norris DP, Brockdorff N, Rastan S. Methylation status of CpG-rich islands on active and inactive mouse X chromosomes. Mamm Genome. 1991; 1:78–83. [PubMed: 1799791]

Ohhata T, Wutz A. Reactivation of the inactive X chromosome in development and reprogramming. Cell Mol Life Sci. 2012; 70:2443–2461. [PubMed: 23052214]

Ohno S, Hauschka TS. Allocycly of the X-chromosome in tumors and normal tissues. Cancer Res. 1960; 20:541–545. [PubMed: 14428472]

Okamoto I, Otte AP, Allis CD, Reinberg D, Heard E. Epigenetic dynamics of imprinted X inactivation during early mouse development. Science. 2004; 303:644–649. [PubMed: 14671313]

Okamoto I, Arnaud D, Le Baccon P, Otte AP, Disteche CM, Avner P, Heard E. Evidence for de novo imprinted X-chromosome inactivation independent of meiotic inactivation in mice. Nature. 2005; 438:369–373. [PubMed: 16227973]

Okamoto I, Patrat C, Thepot D, Peynot N, Fauque P, Daniel N, et al. Eutherian mammals use diverse strategies to initiate X-chromosome inactivation during development. Nature. 2011; 472:370–374. [PubMed: 21471966]

Padeken J, Heun P. Nucleolus and nuclear periphery: velcro for heterochromatin. Curr Opin Cell Biol. 2014; 28:54–60. [PubMed: 24690547]

Payer B, Lee JT. X chromosome dosage compensation: how mammals keep the balance. Annu Rev Genet. 2008; 42:733–772. [PubMed: 18729722]

Penny GD, Kay GF, Sheardown SA, Rastan S, Brockdorff N. Requirement for *Xist* in X chromosome inactivation. Nature. 1996; 379:131–137. [PubMed: 8538762]

Pinter SF, Sadreyev RI, Yildirim E, Jeon Y, Ohsumi TK, Borowsky M, Lee JT. Spreading of X chromosome inactivation via a hierarchy of defined Polycomb stations. Genome Res. 2012; 22:1864–1876. [PubMed: 22948768]

Plath K, Mlynarczyk-Evans S, Nusinow DA, Panning B. *Xist* RNA and the mechanism of x chromosome inactivation. Annu Rev Genet. 2002; 36:233–278. [PubMed: 12429693]

Rao SS, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell. 2014; 159:1665–1680. [PubMed: 25497547]

Riggs AD. X inactivation, differentiation, and DNA methylation. Cytogenet Cell Genet. 1975; 14:9–25. [PubMed: 1093816]

Russell LB. Another Look at the Single-Active-X Hypothesis. Trans N Y Acad Sci. 1964; 26:726–736. [PubMed: 14155929]

Santos-Reboucas CB, Fintelman-Rodrigues N, Jensen LR, Kuss AW, Ribeiro MG, Campos M, et al. A novel nonsense mutation in KDM5C/JARID1C gene causing intellectual disability, short stature and speech delay. Neurosci Lett. 2011; 498:67–71. [PubMed: 21575681]

Schultz MD, He Y, Whitaker JW, Hariharan M, Mukamel EA, Leung D, et al. Human body epigenome maps reveal noncanonical DNA methylation variation. Nature. 2015; 523:212–216. [PubMed: 26030523]

Sharp AJ, Spotswood HT, Robinson DO, Turner BM, Jacobs PA. Molecular and cytogenetic analysis of the spreading of X inactivation in X;autosome translocations. Hum Mol Genet. 2002; 11:3145–3156. [PubMed: 12444099]

Simensen RJ, Rogers RC, Collins JS, Abidi F, Schwartz CE, Stevenson RE. Short-term memory deficits in carrier females with KDM5C mutations. Genet Couns. 2013; 23:31–40. [PubMed: 22611640]

Simon MD, Pinter SF, Fang R, Sarma K, Rutenberg-Schoenberg M, Bowman SK, et al. High-resolution *Xist* binding maps reveal two-step spreading during X-chromosome inactivation. Nature. 2013; 504:465–469. [PubMed: 24162848]

Splinter E, de Wit E, Nora EP, Klous P, van de Werken HJ, Zhu Y, et al. The inactive X chromosome adopts a unique three-dimensional conformation that is dependent on *Xist* RNA. Genes Dev. 2011; 25:1371–1383. [PubMed: 21690198]

Sugimoto M, Abe K. X chromosome reactivation initiates in nascent primordial germ cells in mice. PLoS Genet. 2007; 3:e116. [PubMed: 17676999]

Sun Z, Prodduturi N, Sun SY, Thompson EA, Kocher JA. Chromosome X genomic and epigenomic aberrations and clinical implications in breast cancer by base resolution profiling. Epigenomics. 2015:1–12.

Sunwoo H, Wu JY, Lee JT. The *Xist* RNA-PRC2 complex at 20-nm resolution reveals a low *Xist* stoichiometry and suggests a hit-and-run mechanism in mouse cells. Proc Natl Acad Sci USA. 2015; 112:E4216–E4225. [PubMed: 26195790]

Takagi N, Sasaki M. Preferential inactivation of the paternally derived X chromosome in the extraembryonic membranes of the mouse. Nature. 1975; 256:640–642. [PubMed: 1152998]

Tang YA, Huntley D, Montana G, Cerase A, Nesterova TB, Brockdorff N. Efficiency of *Xist*-mediated silencing on autosomes is linked to chromosomal domain organisation. Epigenet Chromatin. 2010; 3:10.

Tartaglia N, Cordeiro L, Howell S, Wilson R, Janusz J. The spectrum of the behavioral phenotype in boys and adolescents 47, XXY (Klinefelter syndrome). Pediatr Endocrinol Rev. 2010a; 8(suppl 1):151–159. [PubMed: 21217607]

Tartaglia NR, Howell S, Sutherland A, Wilson R, Wilson L. A review of trisomy X (47,XXX). Orphanet J Rare Dis. 2010b; 5:8. [PubMed: 20459843]

Thorvaldsen JL, Krapp C, Willard HF, Bartolomei MS. Nonrandom X chromosome inactivation is influenced by multiple regions on the murine X chromosome. Genetics. 2012; 192:1095–1107. [PubMed: 22887817]

Vallot C, Ouimette JF, Makhlouf M, Feraud O, Pontis J, Come J, et al. Erosion of X chromosome inactivation in human pluripotent cells initiates with XACT coating and depends on a specific heterochromatin landscape. Cell Stem Cell. 2015; 16:533–546. [PubMed: 25921272]

Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood. 2015; 125:13–21. [PubMed: 25320243]

van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet. 2009; 41:521–523. [PubMed: 19330029]

Venolia L, Gartler SM. Comparison of transformation efficiency of human active and inactive X-chromosomal DNA. Nature. 1983; 302:82–83. [PubMed: 6681866]

Venolia L, Gartler SM, Wassman ER, Yen P, Mohandas T, Shapiro LJ. Transformation with DNA from 5-azacytidine-reactivated X chromosomes. Proc Natl Acad Sci USA. 1982; 79:2352–2354. [PubMed: 6179098]

Ware CB, Nelson AM, Mecham B, Hesson J, Zhou W, Jonlin EC, et al. Derivation of naive human embryonic stem cells. Proc Natl Acad Sci USA. 2014; 111:4484–4489. [PubMed: 24623855]

Wareham KA, Lyon MF, Glenister PH, Williams ED. Age related reactivation of an X-linked gene. Nature. 1987; 327:725–727. [PubMed: 3600770]

Welshons WJ, Russell LB. The Y-chromosome as the bearer of male determining factors in the mouse. Proc Natl Acad Sci USA. 1959; 45:560–566. [PubMed: 16590413]

West JD, Frels WI, Chapman VM, Papaioannou VE. Preferential expression of the maternally derived X chromosome in the mouse yolk sac. Cell. 1977; 12:873–882. [PubMed: 597862]

Wu H, Luo J, Yu H, Rattner A, Mo A, Wang Y, et al. Cellular resolution maps of X chromosome inactivation: implications for neural development, function, and disease. Neuron. 2014; 81:103–119. [PubMed: 24411735]

Wutz A, Rasmussen TP, Jaenisch R. Chromosomal silencing and localization are mediated by different domains of *Xist* RNA. Nat Genet. 2002; 30:167–174. [PubMed: 11780141]

Yang F, Babak T, Shendure J, Disteche CM. Global survey of escape from X inactivation by RNA-sequencing in mouse. Genome Res. 2010; 20:614–622. [PubMed: 20363980]

Yang F, Deng X, Ma W, Berletch JB, Rabaia N, Wei G, et al. The lncRNA Firre anchors the inactive X chromosome to the nucleolus by binding CTCF and maintains H3K27me3 methylation. Genome Biol. 2015:1–17. [PubMed: 25583448]

Yildirim E, Kirby JE, Brown DE, Mercier FE, Sadreyev RI, Scadden DT, Lee JT. *Xist* RNA is a potent suppressor of hematologic cancer in mice. Cell. 2013; 152:727–742. [PubMed: 23415223]

Zhang LF, Huynh KD, Lee JT. Perinucleolar targeting of the inactive X during S phase: evidence for a role in the maintenance of silencing. Cell. 2007; 129:693–706. [PubMed: 17512404]

Zinn AR, Roeltgen D, Stefanatos G, Ramos P, Elder FF, Kushner H, et al. A Turner syndrome neurocognitive phenotype maps to Xp22.3. Behav Brain Funct. 2007; 3:24. [PubMed: 17517138]

Figure 1.
(a) Female mouse with the Cattanach insertion [Is(In7;X)1Ct] shows variegation of her coat colour due to spreading of XCI in the inserted portion of chromosome 7, which silences coat colour markers. (b) Nucleus from a female mouse fibroblast after *Xist* RNA-FISH (green). The inactive X is coated with *Xist* RNA.

Figure 2.
Differences and commonalities in the distribution of genes (pink) that escape X inactivation on the mouse X chromosome (centromere to the left) between tissues *in vivo*: ovary (top), spleen (middle), and brain (bottom). Pink bars indicate the position of escape genes on schematics of the mouse X chromosome (centromere at left) (see Berletch *et al.* 2015).